EMEA announced that the Eudra GMP database became publicly available on Aug. 1. The database includes manufacturing authorizations approved and GMP certificates issued by competent authorities, as well as manufacturers that have not complied with GMPs. Non-compliance statements are issued in cases of severe GMP infractions. The Eudra GMP database was initially launched in April 2007 to facilitate the exchange of information on compliance with GMPs between EU competent authorities. EMEA said that the database was launched in a drive for more openness and transparency. Commercial, personal and other types of confidential information will not be publicly available. The database will be updated by competent authorities on an ongoing basis. EMEA announced that "for some competent authorities, the publicly available information in the database is limited at this time.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.